Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$14.77 -2.2%	$14.70	$12.79 ▼ $55.70	$1.54B	0.98	1.82 million shs	2.46 million shs
COGT Cogent Biosciences	$11.40 -0.2%	$8.62	$3.72 ▼ $12.97	$1.30B	0.35	4.80 million shs	1.47 million shs
GLUE Monte Rosa Therapeutics	$4.79 -3.2%	$4.95	$3.50 ▼ $12.40	$304.47M	1.42	439,912 shs	578,534 shs
VERA Vera Therapeutics	$20.95 +0.8%	$22.90	$18.53 ▼ $51.61	$1.33B	1.17	859,998 shs	1.00 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	-1.88%	+9.45%	0.00%	-35.11%	-62.45%
COGT Cogent Biosciences	-0.18%	-5.55%	+53.85%	+94.21%	+20.89%
GLUE Monte Rosa Therapeutics	-3.23%	-15.52%	+1.27%	-3.62%	+5.97%
VERA Vera Therapeutics	+0.77%	-3.94%	-11.42%	-17.23%	-42.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHVN Biohaven	2.3606 of 5 stars	3.5	1.0	2.4	2.5	0.6
COGT Cogent Biosciences	2.8806 of 5 stars	4.4	1.0	2.4	1.7	0.6
GLUE Monte Rosa Therapeutics	1.262 of 5 stars	3.3	0.0	0.6	1.7	0.6
VERA Vera Therapeutics	3.4856 of 5 stars	4.6	1.0	3.3	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	3.07	Buy	$58.46	295.81% Upside
COGT Cogent Biosciences	2.82	Moderate Buy	$18.70	64.04% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$15.33	220.11% Upside
VERA Vera Therapeutics	3.10	Buy	$65.00	210.26% Upside

Current Analyst Ratings Breakdown

Latest GLUE, BHVN, VERA, and COGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	COGT Cogent Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/8/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $22.00
7/8/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/8/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
7/7/2025	COGT Cogent Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $28.00
7/7/2025	COGT Cogent Biosciences	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/30/2025	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
6/18/2025	BHVN Biohaven	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$68.00 ➝ $55.00
6/17/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/3/2025	VERA Vera Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
GLUE Monte Rosa Therapeutics	$75.62M	3.90	N/A	N/A	$3.63 per share	1.32
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	$9.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/5/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
GLUE Monte Rosa Therapeutics	-$72.70M	$0.08	59.88	N/A	N/A	3.86%	2.65%	1.65%	8/14/2025 (Estimated)
VERA Vera Therapeutics	-$152.15M	-$3.00	N/A	N/A	N/A	N/A	-40.59%	-34.54%	8/6/2025 (Estimated)

Latest GLUE, BHVN, VERA, and COGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q1 2025	BHVN Biohaven	-$1.94	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	GLUE Monte Rosa Therapeutics	-$0.31	N/A	N/A	N/A	$7.23 million	N/A
8/14/2025	Q2 2025	VERA Vera Therapeutics	-$0.82	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.54	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A
5/8/2025	Q1 2025	GLUE Monte Rosa Therapeutics	-$0.24	$0.57	+$0.81	$0.57	$13.57 million	$84.93 million
5/8/2025	Q1 2025	VERA Vera Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	N/A	N/A
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
VERA Vera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	N/A	2.33	2.33
COGT Cogent Biosciences	N/A	5.13	5.13
GLUE Monte Rosa Therapeutics	N/A	5.61	5.61
VERA Vera Therapeutics	0.10	27.68	27.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
COGT Cogent Biosciences	N/A
GLUE Monte Rosa Therapeutics	79.96%
VERA Vera Therapeutics	99.21%

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	16.00%
COGT Cogent Biosciences	7.29%
GLUE Monte Rosa Therapeutics	6.90%
VERA Vera Therapeutics	16.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	239	102.11 million	85.78 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
GLUE Monte Rosa Therapeutics	90	61.51 million	57.27 million	Optionable
VERA Vera Therapeutics	40	63.77 million	53.38 million	Optionable

GLUE, BHVN, VERA, and COGT Headlines

Recent News About These Companies

Federated Hermes Inc. Cuts Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)

5 hours ago | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Short Interest Up 5,059.7% in July

August 2 at 2:27 AM | americanbankingnews.com

Polycythemia Vera Market Expands as FDA Fast Tracks New Treatments and Clinical Trials Show Promising Results | DelveInsight

August 1 at 1:02 PM | theglobeandmail.com

RAPT Therapeutics (RAPT) was upgraded to a Hold Rating at J.P. Morgan

August 1 at 2:59 AM | theglobeandmail.com

Decheng Capital LLC Cuts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

July 31 at 6:21 AM | marketbeat.com

Y Intercept Hong Kong Ltd Makes New $293,000 Investment in Vera Therapeutics, Inc. (NASDAQ:VERA)

July 31 at 6:21 AM | marketbeat.com

Behind The Volatility Of Vera Therapeutics

July 27, 2025 | seekingalpha.com

Victory Capital Management Inc. Lowers Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

July 27, 2025 | marketbeat.com

GW&K Investment Management LLC Grows Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

July 23, 2025 | marketbeat.com

Vera Therapeutics, Inc. (NASDAQ:VERA) Stake Decreased by Jennison Associates LLC

July 21, 2025 | marketbeat.com

Startup targets orphan kidney disease with former Merck drug

July 17, 2025 | medcitynews.comM

Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from Brokerages

July 15, 2025 | marketbeat.com

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2025 | globenewswire.com

Vera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA Nephropathy

July 6, 2025 | msn.com

Vera Therapeutics Inc Class A Sustainability - Morningstar

July 5, 2025 | morningstar.comM

Vera Therapeutics director Enright buys shares worth $5.2m

June 27, 2025 | investing.com

Vor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in Funding

June 27, 2025 | msn.com

Insider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of Stock

June 26, 2025 | insidertrades.com

Polycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsight

June 24, 2025 | theglobeandmail.com

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

June 24, 2025 | finance.yahoo.com

J.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)

June 19, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike?
By Nathan Reiff | July 22, 2025
View D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike?
Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded
By Leo Miller | July 10, 2025
View Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded
3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
By Chris Markoch | July 14, 2025
View 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
Newmont's Financial Strength Sets a High Bar for Gold Miners
By Jeffrey Neal Johnson | August 1, 2025
View Newmont's Financial Strength Sets a High Bar for Gold Miners
Top 5 AI & Autonomy Stocks Trading Under $15 With Big Potential
By Ryan Hasson | July 28, 2025
View Top 5 AI & Autonomy Stocks Trading Under $15 With Big Potential

GLUE, BHVN, VERA, and COGT Company Descriptions

Biohaven NYSE:BHVN

$14.77 -0.33 (-2.19%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$14.59 -0.18 (-1.25%)

As of 08/1/2025 08:00 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Cogent Biosciences NASDAQ:COGT

$11.40 -0.02 (-0.18%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$11.90 +0.50 (+4.43%)

As of 08/1/2025 05:07 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Monte Rosa Therapeutics NASDAQ:GLUE

$4.79 -0.16 (-3.23%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$4.79 0.00 (0.00%)

As of 08/1/2025 04:10 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Vera Therapeutics NASDAQ:VERA

$20.95 +0.16 (+0.77%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$20.94 -0.01 (-0.05%)

As of 08/1/2025 06:15 PM Eastern

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time